Search results for "Dot"

showing 10 items of 5147 documents

Antibodies to vascular endothelial cells in chronic rejection of renal allografts.

2000

AdultCytotoxicity ImmunologicGraft RejectionMalePathologymedicine.medical_specialtyTime FactorsAdolescentT-LymphocytesIsoantibodiesMedicineHumansTransplantation HomologousBlood TransfusionCells CulturedImmunosuppression TherapyTransplantationKidneyB-Lymphocytesbiologybusiness.industryHistocompatibility Antigens Class IMiddle AgedKidney TransplantationTransplantationEndothelial stem cellmedicine.anatomical_structureImmunologyHumoral immunityAntibody Formationbiology.proteinSurgeryFemaleEndothelium VascularAntibodybusinessBlood vesselFollow-Up StudiesTransplantation proceedings
researchProduct

Mechanical–biological waste treatment and the associated occupational hygiene in Finland

2004

A special feature of waste management in Finland has been the emphasis on the source separation of kitchen biowaste (catering waste); more than two-thirds of the Finnish population participates in this separation. Source-separated biowaste is usually treated by composting. The biowaste of about 5% of the population is handled by mechanical-biological treatment. A waste treatment plant at Mustasaari is the only plant in Finland using digestion for kitchen biowaste. For the protection of their employees, the plant owners commissioned a study on environmental factors and occupational hygiene in the plant area. During 1998-2000 the concentrations of dust, microbes and endotoxins and noise level…

AdultEngineeringbusiness.product_categoryThreshold limit valuePopulationAir MicrobiologyAir Pollutants OccupationalOccupational safety and healthWaste ManagementOccupational hygieneOccupational ExposureBiological wasteHumansRespiratoreducationWaste Management and DisposalFinlandOccupational Healtheducation.field_of_studyWaste managementbusiness.industryDry coughTemperatureDustHumidityEndotoxinsWaste treatmentNoise OccupationalbusinessWaste Management
researchProduct

Endothelin-1 and endothelin receptor status in kidney transplants undergoing acute rejection.

1999

Abstract Endothelin-1 (ET-1) is a potent vasoconstrictor with vasopressor and mitogenic effects. Blood samples were collected from 21 renal transplant patients undergoing acute rejection at the time of diagnostic kidney biopsy: there were 20 men and one woman, mean age 35.6 years. All patients were on triple immunosuppressive therapy with cyclosporine A, azathioprine and methylprednisolone. Twenty living kidney donors pre-uninephrectomy (11 men and nine women, mean age 34 years) served as controls. Control kidney was obtained from fresh autopsy material and normal kidney tissue from nephrectomies for malignancy. Mean plasma ET-1 was significantly increased at 1.56±0.2 pg ml −1 during acute …

AdultGraft RejectionMalemedicine.medical_specialtyAdolescentUrinary systemUrologyAzathioprineInternal medicineBlood plasmaBiopsymedicineHumansImage CytometryPharmacologyKidneymedicine.diagnostic_testEndothelin-1business.industryReceptors EndothelinMiddle AgedReceptor Endothelin AEndothelin 1ImmunohistochemistryKidney TransplantationReceptor Endothelin BTransplantationEndocrinologymedicine.anatomical_structureAcute DiseaseFemaleEndothelin receptorbusinessmedicine.drugImmunopharmacology
researchProduct

Transient CD15-positive endothelial phenotype in the human placenta correlates with physiological and pathological fetoplacental immaturity

2013

Abstract Objective Placental growth and villous maturation are critical parameters of placental function at the end of pregnancy. A failure in these processes leads to the development of placental dysfunction, as well as fetal and neonatal mortality and morbidity. The aim of the study was to determine the relevant diagnostic markers associated with pathological placental development. Study design Forty tissue samples from normal placentas of different gestational age and 68 pathological term placentas with defective villous maturation (GDM, idiopathic IUFD, preeclamsia, HELLP syndrome) comprised the comparative immunohistochemical study (CD15, CD45 and CD34). Positive immunohistochemical re…

AdultHELLP SyndromePathologymedicine.medical_specialtyStromal cellEndotheliumHELLP syndromePlacentaCD34Lewis X AntigenAntigens CD34Gestational AgePre-EclampsiaPregnancymedicineHumansPathologicalPregnancyFetusFetal Growth Retardationbusiness.industryEndothelial CellsObstetrics and GynecologyFucosyltransferasesmedicine.diseaseImmunohistochemistryPlacentationDiabetes Gestationalmedicine.anatomical_structureReproductive MedicineCase-Control Studiesembryonic structuresLeukocyte Common AntigensImmunohistochemistryFemalebusinessEuropean Journal of Obstetrics & Gynecology and Reproductive Biology
researchProduct

Physiological Estrogen Replacement May Enhance the Effectiveness of the Gonadotropin-Releasing Hormone Agonist in the Treatment of Hirsutism

1994

GnRH agonists (GnRH-A) have been used for the treatment of hirsutism in women with ovarian hyperandrogenism. However, significant side-effects, including vasomotor symptoms and bone loss, have prevented the long term use of this therapy. In this study, we evaluated the effects of low dose (physiological) estrogen replacement on the side-effects and clinical and hormonal parameters of 22 hirsute women with ovarian hyperandrogenism when treated with a long-acting GnRH-A, Decapeptyl. Ten patients with Ferriman-Gallwey (FG) scores averaging 13.4 +/- 1.5 were randomly assigned to be treated with Decapeptyl alone (3.75 mg, im, every 28 days for 6 months), and 12 other patients with FG scores aver…

AdultHirsutismendocrine systemmedicine.medical_specialtyAdolescentmedicine.drug_classEndocrinology Diabetes and MetabolismClinical BiochemistryOvaryMedroxyprogesterone AcetateGonadotropin-releasing hormoneBiochemistryGonadotropin-Releasing HormoneEndocrinologyGonadotropin-releasing hormone agonistInternal medicinemedicineHumansMedroxyprogesterone acetateEstrogen replacementConjugated Equine EstrogensTestosteronehirsutismTriptorelin PamoateVasomotorbusiness.industryEstrogen Replacement TherapyBiochemistry (medical)HyperandrogenismObstetrics and GynecologyDrug SynergismGeneral Medicinemedicine.diseaseMenstruationmedicine.anatomical_structureEndocrinologyEstrogenGonadotropins PituitaryAndrogensDrug Therapy CombinationFemalebusinesshormones hormone substitutes and hormone antagonistsHormonemedicine.drugObstetrical & Gynecological Survey
researchProduct

The endocrine pattern of late onset adrenal hyperplasia (21-hydroxylase deficiency)

1984

We describe 5 adult women with severe hirsutism due to late onset 21-hydroxylase deficiency. Diagnosis was performed on the finding of high serum 17-hydroxyprogesterone (17OHP) levels with a marked hyperresponse to an ACTH test. The endocrine study showed in most patients a gonadotropin behavior similar to that observed in classical polycystic ovary (PCO) syndrome. Prolactin levels were slightly increased in basal conditions and presented an exaggerated response to TRH stimulation.

AdultHirsutismendocrine systemmedicine.medical_specialtyAdolescentmedicine.drug_classEndocrinology Diabetes and MetabolismLate onsetEndocrinologyAdrenocorticotropic HormoneInternal medicineHydroxyprogesteronesmedicineHumansEndocrine systemGonadal Steroid HormoneshirsutismAdrenal Hyperplasia Congenitalbiologybusiness.industry17-alpha-HydroxyprogesteroneVirilization21-HydroxylaseLuteinizing Hormonemedicine.diseasePolycystic ovaryProlactinProlactinEndocrinologySteroid Hydroxylasesbiology.proteinFemaleSteroid 21-HydroxylaseFollicle Stimulating Hormonemedicine.symptomGonadotropinbusinesshormones hormone substitutes and hormone antagonistsJournal of Endocrinological Investigation
researchProduct

The autoantigen La/SS-B: Analysis of the expression of alternatively spliced La mRNA isoforms

1996

The gene for the nuclear autoantigen La/SS-B encodes two La mRNA isoforms. In order to study the function and expression of both La mRNA forms, an in situ hybridization procedure was developed allowing the selective identification of either exon 1 or exon 1'. For this purpose, digoxigenin-labeled exon-specific sense and anti-sense probes were prepared by in vitro transcription from plasmids that contained the respective exon sequence. Detection of the probes was carried out by using rhodamine-conjugated anti-digoxigenin antibody and confocal laser scanning microscopy. Both La mRNAs were found in the cytoplasm of endothelial cells but not in smooth muscle cells. In addition to the in situ te…

AdultHistologyMolecular Sequence DataGene ExpressionIn situ hybridizationBiologyAutoantigensPolymerase Chain ReactionPathology and Forensic MedicineExonExon trappingIsomerismGene expressionHumansSaphenous VeinEndotheliumRNA MessengerMammary ArteriesGeneIn Situ HybridizationMessenger RNABase SequenceExonsCell BiologyMolecular biologyAlternative SplicingLiverRibonucleoproteinsCytoplasmPrimer (molecular biology)DNA ProbesTranscription Factors
researchProduct

Unilateral laryngeal and hypoglossal paralysis (Tapia's syndrome) in a patient with an inflammatory pseudotumor of the neck

2012

Tapia’s syndrome (TS) is a rare condition thought tobe causedby njury to the extracranial course of both recurrent laryngeal branch f the vagal nerve and hypoglossal nerve. First described in 1904, t occurs with unilateral paralysis of the vocal cord and tongue, ith normal function of the soft palate. Commonly reported causes re direct trauma, neurofibromatosis of X and XII nerves, carotid rtery dissection involving the ascending pharyngeal artery, and isplacement of endotracheal tube during general anesthesia [1].

AdultHypoglossal Nerve DiseasesGranuloma Plasma CellTongueTonguemedicine.arterymedicineParalysisHumansNeurofibromatosisNeurologic ExaminationSoft palateElectromyographybusiness.industryNeck tumors cranial nervesAscending pharyngeal arterySyndromeGeneral MedicineAnatomymedicine.diseaseMagnetic Resonance ImagingDissectionmedicine.anatomical_structureInflammatory pseudotumorFemaleSurgeryNeurology (clinical)Atrophymedicine.symptomTomography X-Ray ComputedbusinessVocal Cord ParalysisHypoglossal nerveNeckClinical Neurology and Neurosurgery
researchProduct

Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis

2011

Objective: To analyze the impact of LH administration on cycle outcome in ovarian stimulation with GnRH antagonists. Design: Randomized, open-label, controlled trial performed in two age subgroups. Recombinant (r) FSH versus rFSH + rLH administration was compared. Setting: University-affiliated private infertility clinic. Patient(s): Up to 35 years old (n = 380) and aged 36 to 39 years (n = 340), undergoing their first or second IVF cycle. Intervention(s): Recombinant LH administration since stimulation day 1. Main Outcome Measure(s): Implantation rate, ongoing pregnancy rate. Result(s): In the young population, implantation rates were similar: 27.8% versus 28.6%, odds ratio (OR) 1.03 (95% …

AdultInfertilitymedicine.medical_specialtyPregnancy Ratemedicine.drug_classmedicine.medical_treatmentGonadotropin-releasing hormone antagonistGonadotropin-Releasing HormoneOvulation InductionPregnancymedicineGnRH antagonistHumansEmbryo ImplantationSperm Injections IntracytoplasmicGynecologyPregnancyIn vitro fertilisationbusiness.industryObstetrics and GynecologyOdds ratioLuteinizing Hormonemedicine.diseaseRecombinant ProteinsConfidence intervalPregnancy rateReproductive Medicineluteinizing hormoneDrug Therapy CombinationFemaleOvarian stimulationFollicle Stimulating HormoneLuteinizing hormonebusinessInfertility Femalein vitro fertilizationMaternal Age
researchProduct

Recombinant follicle stimulating hormone stimulation in poor responders with normal basal concentrations of follicle stimulating hormone and oestradi…

1999

A total of 30 young infertile patients who exhibited a poor response in two previous consecutive cycles, despite having normal basal follicle stimulating hormone (FSH) and oestradiol concentrations, were invited to participate in a prospective randomized study comparing the clinical efficacy of recombinant (rFSH) and urinary (uFSH) follicle stimulating hormone. An evaluation of the total dose used (3800 IU versus 4600 IU, P < 0.05) and duration of treatment (10.2 days versus 13.2 days, P < 0.05) showed a significantly shorter treatment period as well as a significantly lower total dose of FSH required to induce ovulation successfully in the group of patients treated with rFSH. Significantly…

AdultInfertilitymedicine.medical_specialtymedicine.drug_classUrinary systemmedia_common.quotation_subjectBiologyBasal (phylogenetics)Follicle-stimulating hormoneOvulation InductionPregnancyInternal medicinemedicineHumansEmbryo ImplantationProspective StudiesOvulationmedia_commonPregnancyEstradiolRehabilitationPregnancy OutcomeObstetrics and Gynecologymedicine.diseaseRecombinant ProteinsEndocrinologyReproductive MedicineEstrogenFemaleFollicle Stimulating HormoneGonadotropinHuman Reproduction
researchProduct